Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Research Abstract |
(1) We identified ARFGAP3 as a primary androgen target genes that interacted with paxillin and enhanced androgen receptor (AR) activity in LNCaP cells. (2) Our previous chromatin immunoprecipitation combined with DNA microarray showed that the upstream region of AX3 includes a functional AR binding site, which was a putative AX3 enhancer. We found that two AR response elements (AREs) and one Oct1 binding site cooperatively regulate this putative AX3 enhancer in an androgen-dependent manner. (3) We developed novel synthetic pyrrole-imidazole (PI) polyamides targeting this Oct1 binding sites to control AX3 expression. Treatment of this polyamide showed suppressed AX3 mRNA expression and the proliferation of LNCaP cells. (4) We found the novel androgen responsive gene ARG1, and performed functional analysis for ARG1 works in prostate cancer.
|